Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.58 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689498 | 1.00 | MAOB (0.64) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL7054652 | 0.87 | ABCG2 (0.63) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL7054651 | 0.87 | ABCG2 (0.63) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL691132 | 0.84 | NPC1 (0.69) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL874615 | 0.84 | MAPT (0.66) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL691131 | 0.84 | NPC1 (0.69) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL17212246 | 0.84 | MAPT (0.66) | MAOBMAPTNPC1RAB9AKDM4E | |
| SCHEMBL11697859 | 0.83 | ABCG2 (0.59) | ABCG2TP53 | |
| SCHEMBL10623141 | 0.83 | ABCG2 (0.59) | ABCG2TP53 | |
| SCHEMBL6364344 | 0.83 | ABCG2 (0.59) | ABCG2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252273-B2 | Ultraviolet absorber | LEAD CHEMICAL CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2192106-B1 | ULTRAVIOLET ABSORBER | LEAD CHEM CO LTD (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20100239508-A1 | ULTRAVIOLET ABSORBER | LEAD CHEMICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2192106-A1 | ULTRAVIOLET ABSORBER | Lead Chemical Co. Ltd. (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6713482-B2 | SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS | PFIZER INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| US-6093518-A | Visible laser-curable composition | KANSAI PAINT CO., LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| US-5939148-A | Visible laser-curable composition | KANSAI PAINT CO., LTD. (JP) | 1999-08-17 | — | — | US | disclosed |
| EP-0435262-B1 | Visible radiation sensitive composition | KANSAI PAINT CO LTD (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-5102775-A | Sensitizer, water insoluble photoinitiator and nitrogen containing compound | KANSAI PAINT CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0435262-A2 | Visible radiation sensitive composition | KANSAI PAINT CO., LTD. (JP) | 1991-07-03 | — | — | EP | disclosed |
| US-4189484-A | Antihypertensive quinazoline derivatives | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239508-A1 | ULTRAVIOLET ABSORBER | UNG, UACA, ABCG2 | MAOB 49/4885MAPT 564/4885NPC1 2126/4885 |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | MAOB 3180/4885MAPT 4772/4885NPC1 2771/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | MAOB 3252/4885MAPT 4736/4885NPC1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.